Rolicyclidine

Pre-existing cardiovascular disease, hypertension, arrhythmias, or history of stroke increases risk of adverse cardiovascular events. PCP-class compounds elevate heart rate and blood pressure in a dose-dependent manner.

Conditions including COPD, asthma, sleep apnea, or any respiratory insufficiency increase the risk of respiratory depression, particularly at higher doses or in combination with other CNS depressants.

Individuals with epilepsy or lowered seizure threshold face increased risk. While NMDA antagonism is generally anticonvulsant, the paradoxical cortical disinhibition produced by PCP-class drugs at high doses may provoke seizures.

Rolicyclidine and all PCP-class dissociatives are potent psychotomimetics. Administration to individuals with schizophrenia, schizoaffective disorder, or other psychotic disorders risks severe psychiatric destabilization, prolonged psychotic episodes, and hospitalization.

Bipolar disorder increases susceptibility to drug-induced psychosis and mania. Rolicyclidine's combined NMDA antagonism and inferred dopaminergic activity may trigger destabilizing episodes.

Hepatic impairment may prolong rolicyclidine's duration of action and exacerbate its mechanism-based CYP inhibition, increasing both direct toxicity risk and drug-drug interaction potential.

Pregnancy is an absolute contraindication for all PCP-class dissociatives. NMDA antagonism during fetal development causes neuroapoptosis in animal models, and PCP-class compounds cross the placental barrier.